News

The collaboration follows the recent acquisition of the technology for the manufacture of IFNα by Neovacs from AMEGABIOTECH. This license agreement will allow Neovacs to directly transfer AMEGABIOTECH's

EGPA is a rare disease in which patients suffer from inflammation that is widespread in the walls of small blood vessels. The treatment aims is to induce and

The equity consideration for the 85.1% stake is $24m. Sun Pharma would also assume a debt of approximately $36m as part of this transaction. Biosintez is a Russian

The trial demonstrated that patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo. The company said it

The company’s latest report states that the impressive strength of the market over the next decade can be attributed to the increasing incorporation of premium-priced immune checkpoint inhibitors

Allergan acquired Chase for an upfront payment of $125 million (subject to certain adjustments) and additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201,

Opdivo is now the first and only programmed death-1 (PD-1) inhibitor approved for a hematologic malignancy in the European Union (EU). It is the company’s second immuno-oncology agent

In July 2016, daratumumab was granted a Breakthrough Therapy Designation (BTD) in this patient population.  In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to

The Swiss drugmaker exercised its right to buy Selexys following a successful phase II trial to evaluate the latter’s investigational drug SelG1 for reducing vaso-occlusive pain crises in